| 摘要: |
| ［摘要］ 非小细胞肺癌（non-small cell lung cancer,NSCLC）是现今世界范围内最常见的恶性肿瘤之一。手术及化疗是其治疗的主要方法，研究和确定临床上NSCLC化疗敏感性预测的靶向分子和指标将有利于NSCLC患者的个体化治疗。该文就核苷酸切除修复交叉互补组1（excision repair cross complementation group 1，ERCC1）基因作为NSCLC化疗疗效预测指标的研究现状作一综述。 |
| 关键词: 非小细胞肺癌 ERCC1 化疗 |
| DOI：10.3969/j.issn.1674-3806.2013.05.36 |
| 分类号:R 734.2 |
| 基金项目:广西科学研究与技术开发计划资助项目（编号：桂科攻10124001A-44） |
|
| ERCC1:A new predictive genomic marker for chemotherapy of non-small cell lung cancer |
|
QIN Guo-liang, XIAN Lei
|
|
First Department of Surgery, Traditional Chinese Medicine Hospital of Hechi, Guangxi 547000, China
|
| Abstract: |
| ［Abstract］ Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Surgery and chemotherapy are the main methods in therapy of NSCLC. The study and identification of predictive targeting molecules and markers of chemosensitivity of NSCLC will be beneficial to customized treatment of NSCLC patients. This article will review the research status about excision repair cross complementation group 1(ERCC1) as a predictive marker for chemotherapy of NSCLC. |
| Key words: Non-small cell lung cancer（NSCLC） Excision repair cross complementation group 1(ERCC1) Chemotherapy |
